Invest in Vegalab
Scalable biotech platform in agrobiologicals, biosecurity, water and cosmetics - proprietary nano-encapsulation technology, 40–80% gross margins and a capital-efficient international expansion model.
Company snapshot
Vegalab SA is a Swiss biotech enterprise headquartered in Zug, Switzerland. We develop and manufacture natural product solutions utilising proprietary formulation technologies - including micronization and nano-encapsulation - that enhance stability, penetration and performance while maintaining cost competitiveness against conventional synthetic alternatives.
Our operations span four business verticals - Crop Science, Beauty Science, Life Sciences and Biosecurity - all built on a single shared technology platform. This gives us diversified revenue streams with shared R&D economics and a clear path to cross-vertical leverage as the platform matures.
Vegalab products are registered with state departments of agriculture across the United States, and with the relevant authorities in the other markets we serve. Registration status varies by product and jurisdiction. Details are available on request.
FDA does not approve cosmetics. Not ours, not anyone's. There is no FDA approval, no FDA certification and no FDA certificate for a cosmetic product anywhere in the United States. FDA's own words are that cosmetic registration and listing "is neither a cosmetic approval program nor a promotional tool", and that FDA does not issue certificates for cosmetics.
What does exist, since the Modernization of Cosmetics Regulation Act, is a mandatory filing: facilities register, and products are listed with their ingredients. It is not a review, an endorsement or a quality mark. Vegalab's facility registration and product listing have been filed.
What actually answers your question is documentation, and we will send any of it on request: the full ingredient declaration, and our declaration of conformity to ISO 22716, the international standard for cosmetic good manufacturing practice.
Investment highlights
Six structural advantages that make Vegalab a differentiated opportunity in the natural products biotech sector.
Proprietary technology platform
Multi-layer nano-encapsulation with up to 20 programmable trigger-responsive layers - protecting sensitive actives, improving solubility and controlling release. A genuine moat, not a formulation tweak.
Multi-vertical revenue diversification
Four distinct end-markets (crop, beauty, life sciences, biosecurity) share one R&D infrastructure, reducing risk concentration and creating natural cross-selling and licensing opportunities.
Capital-efficient expansion model
Growth scales through distribution partners and country-level joint ventures with exclusive territory rights. Capital is directed toward inventory, registrations and sales execution - not fixed infrastructure.
Regulatory credentialing
Vegalab products are registered with state departments of agriculture across the United States, and with the relevant authorities in the other markets we serve. Registration status varies by product and jurisdiction. Details are available on request.
Third-party validation
Proof points from commercial distributors, major university trial programmes, independent labs and 200+ industry report references position Vegalab as a credible, established participant - not early-stage.
Structural tailwinds
Global regulatory pressure on synthetic pesticides, consumer demand for clean-label food and cosmetics, and ESG capital flows all favour high-performance natural products. Vegalab is positioned at the centre of this shift.
What investors gain access to
Direct investment or country-level franchise/JV structures with exclusive territory rights and clear paths to liquidity.
US, Canada & international market expansion
Scalable expansion into the US, Canada and high-potential international markets via direct investment into operations and country-level franchise/JV structures - each with exclusive territory rights and a clear path to liquidity.
Documented revenue history
Historical revenues with public audit documentation from prior operations. Gross margin ranges of ~40–80% depending on product and channel mix, validated across both B2B agrochemical and B2C consumer channels.
Franchise and territory models
Country operating companies can be structured as exclusive territory franchises, giving investors both the upside of local market development and the IP leverage of the Vegalab platform without duplicating core R&D spend.
Technology licensing potential
The nano-encapsulation platform has licensing potential beyond current verticals - agrochemical majors, cosmetic contract manufacturers and pharmaceutical delivery applications represent additional monetisation pathways.
Key milestones
Vegalab's trajectory from Swiss startup to multi-vertical, multi-continent biotech operation.
Vegalab SA incorporated in Zug, Switzerland
Nano-encapsulation platform developed; first crop science product line formulated.
First US distribution
Initial distribution agreements signed with US agricultural wholesalers.
Beauty Science launch
NanoSerum skincare line launched under Beauty Science division.
National Hemp Expo award & Asia-Pacific entry
Named Best Fertilizer Company at the National Hemp Expo. Distribution partnerships established in Singapore, South Korea and Hong Kong.
Biosecurity division launch
PureTabs biosecurity product range launched. University trial programme expanded to five institutions.
Active investment round · US & Canada expansion
Seeking capital partners for US/Canada market acceleration and country-level JV structures. Investor materials available under NDA.
Request investor materials
We share detailed financials, technology documentation, trial data and investment structure terms selectively with qualified investors under NDA. If you are a fund, family office, strategic partner or accredited individual investor, we welcome your enquiry.
Request investor materialsLast updated: